FirstString Research, Inc., a clinical stage biotech company, is leading the translation of cell-cell communication and cell-cell contact/adhesion science into a pipeline of drugs and medical applications for scar prevention, inflammation reduction, wound healing, and complex tissue regeneration. The Company has an exclusive worldwide license from the Medical University of South Carolina (MUSC) for the connexin-technology platform and intellectual properties of a portfolio of peptides capable of modulating junctional proteins that are critical for inter-cellular communication. A Phase I human clinical trial demonstrated safety and efficacy of a lead peptide generated from the technology platform. The Company is now advancing GranexinTM Gel, a topical formulation of the lead peptide, through three Phase II human clinical trials for scar reduction and treatment of chronic wounds.